# Absology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/absology

- Industry: Medical Devices & Equipment
- Headquarters: Anyang-si, South Korea
- Website: www.absology.co.kr/
- Total disclosed funding: $15M
- Latest round: Series B (Dec 21, 2023)
- Investors on record: 7

## About

Based in Anyang, South Korea, and founded in 2017, Absology Co., Ltd., formerly Intekbio Co. Ltd., is a field diagnosis-based in vitro immune diagnostic device venture company providing an in-vitro-diagnostic system. As of 2023, the company is led by its CEO Hansang Cho. In December 2025, Absology raised KRW 4 billion in venture funding from Enlight Ventures and Krossroad Partners.

Absology's product offering includes Absol, a POCT analyzer that enables its customer to perform test within 5 minutes or ultra-sensitive immunological tests within 30 minutes. The diagnostic test can be done for testosterone, Vitamin - D, PSA, freeT4, TSH and FT4 combo, PCT, cortisol, cardiac, COVID-19 IgM/IgG combo, COVID-19 Ag, COVID-19 NAb, and TSH & FT4 combo; Absolute HS is a high sensitivity ELISA analyzer for early disease screening and testing time takes about 40 minutes. The test can be perform for cardiovascular, Alzheimer's, and anti-cancer therapy monitoring.

## Funding rounds

- Series B, Dec 21, 2023, $7.7M — Korea Development Bank, Forest Partners, Forest Ventures, Krossroad Partners, INTEKPLUS
- Series A, Nov 11, 2019, $7.7M — Korea Investment Partners, IMM Investment

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- IMM Investment (https://capitalatlas.ai/funds/imm-investment) — Series A
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series B
- Forest Partners (https://capitalatlas.ai/funds/forest-partners) — Series B
- Forest Ventures (https://capitalatlas.ai/funds/forest-ventures) — Series B
- Krossroad Partners (https://capitalatlas.ai/funds/krossroad-partners) — Series B
- INTEKPLUS — Series B